The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1537
ISSUE1537
January 1, 2018
Betrixaban (Bevyxxa) for VTE Prophylaxis in Acute Medical Illness
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Betrixaban (Bevyxxa) for VTE Prophylaxis in Acute Medical Illness
January 1, 2018 (Issue: 1537)
The FDA has approved betrixaban (Bevyxxa –
Portola), a once-daily, oral, direct factor Xa inhibitor,
for prophylaxis of venous thromboembolism (VTE)
in adults hospitalized for an acute medical illness
who have moderately or severely restricted...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.